Cargando…

Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma

Exportin-1 mediates nuclear export of multiple tumor suppressor and growth regulatory proteins. Aberrant expression of exportin-1 is noted in human malignancies, resulting in cytoplasmic mislocalization of its target proteins. We investigated the efficacy of selinexor against liposarcoma cells both...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garg, Manoj, Kanojia, Deepika, Mayakonda, Anand, Said, Jonathan W, Doan, Ngan B, Chien, Wenwen, Ganesan, Trivadi S, Huey, Linda Shyue Chuang, Venkatachalam, Nachiyappan, Baloglu, Erkan, Shacham, Sharon, Kauffman, Michael, Koeffler, H. Phillip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352339/ https://www.ncbi.nlm.nih.gov/pubmed/27893412 http://dx.doi.org/10.18632/oncotarget.13485

Ejemplares similares

Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin
por: Garg, Manoj, et al.
Publicado: (2017)

Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor
por: Subhash, Vinod Vijay, et al.
Publicado: (2018)

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer
por: Arango, Natalia Paez, et al.
Publicado: (2017)

KPT-330 has antitumour activity against non-small cell lung cancer
por: Sun, H, et al.
Publicado: (2014)

A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer
por: Shafique, Michael, et al.
Publicado: (2019)

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
por: Tremblay, Gabriel, et al.
Publicado: (2021)

XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose
por: Crochiere, Marsha L., et al.
Publicado: (2017)

Potential targeted therapeutic approaches in liposarcoma
por: Kanojia, Deepika, et al.
Publicado: (2016)

Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma
por: Gounder, Mrinal, et al.
Publicado: (2021)

KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models
por: Gravina, Giovanni Luca, et al.
Publicado: (2015)

Selective nuclear export inhibitor KPT‑330 enhances the radiosensitivity of esophageal carcinoma cells
por: Xu, Jing, et al.
Publicado: (2023)

Erratum to: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models
por: Gravina, Giovanni Luca, et al.
Publicado: (2016)

Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets
por: Kanojia, Deepika, et al.
Publicado: (2017)

Genomic landscape of liposarcoma
por: Kanojia, Deepika, et al.
Publicado: (2015)

KPT-330 inhibition of chromosome region maintenance 1 is cytotoxic and sensitizes chronic myeloid leukemia to Imatinib
por: Nie, Danian, et al.
Publicado: (2018)

Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death
por: Argueta, Christian, et al.
Publicado: (2018)

KPT330 improves Cas9 precision genome- and base-editing by selectively regulating mRNA nuclear export
por: Cui, Yan-ru, et al.
Publicado: (2022)

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells
por: Etchin, J, et al.
Publicado: (2017)

A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth
por: Rane, Chetan, et al.
Publicado: (2017)

Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway
por: Zhao, Cheng, et al.
Publicado: (2022)

Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial
por: Gounder, Mrinal M., et al.
Publicado: (2022)

Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma
por: Thirasastr, Prapassorn, et al.
Publicado: (2022)

Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas
por: Jeitany, Maya, et al.
Publicado: (2020)

Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma
por: Chen, Ye, et al.
Publicado: (2019)

Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines
por: Breit, Megan N, et al.
Publicado: (2014)

KPT‐330 and Y219 exert a synergistic antitumor effect in triple‐negative breast cancer through inhibiting NF‐κB signaling
por: Wen, Tiantian, et al.
Publicado: (2023)

Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185
por: Tabe, Yoko, et al.
Publicado: (2015)

Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents
por: Kashyap, Trinayan, et al.
Publicado: (2018)

Identification of somatic alterations in lipoma using whole exome sequencing
por: Kanojia, Deepika, et al.
Publicado: (2019)

Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status
por: Marijon, Hélène, et al.
Publicado: (2021)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Gasparetto, Cristina, et al.
Publicado: (2020)

XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis
por: Zhu, Zhi-Chuan, et al.
Publicado: (2019)

A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
por: Lassman, Andrew B., et al.
Publicado: (2022)

Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo
por: Kashyap, Trinayan, et al.
Publicado: (2021)

Selinexor for multiple myeloma
Publicado: (2022)

Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study
por: London, Cheryl A., et al.
Publicado: (2014)

XPO1 Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells
por: Taylor‐Kashton, Cheryl, et al.
Publicado: (2016)

Functional Genome-wide Screening Identifies Targets and Pathways Sensitizing Pancreatic Cancer Cells to Dasatinib
por: Chien, Wenwen, et al.
Publicado: (2018)

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021)

A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds
por: Crochiere, Marsha L., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_10e1n9ssqnkcqmhrua345nfi2b